← All trials
NCT05362695
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 17, 2022
- Primary completion
- Jul 13, 2022
- Completion date
- Jul 13, 2022
- First posted
- May 5, 2022
- Last posted
- Sep 16, 2022
- Enrollment
- 18
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ironwood PharmaceuticalsLead sponsor
- Ironwood PharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.